Santhera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress – Yahoo Finance

Share Article

Pratteln, Switzerland, and Rockville, MD, USA, October 1
0, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of data relating to long-term efficacy, tolerability and the impact of vamorolone on bone health in patients with Duchenne muscular dystrophy (DMD) over 2.5 years of treatment [1].
The data will be shared at the 2022 World Muscle Society (WMS) Congress being held October 11-15, 2022, in Halifax, Nova Scotia, Canada, as follows:
Flash poster presentations
The spine fracture burden in boys with DMD treated with the novel dissociative steroid vamorolone versus deflazacort and prednisone – Leanne Ward, MD, October 12, 14:40-14:45 ADT, #FP.03
Results of a double-blind cross-over trial of vamorolone in Duchenne muscular dystrophy (DMD) – Eric Hoffman, PhD, October 14, 14:40-14:45 ADT, #FP.27
Vamorolone’s impact on height and body mass index in patients with Duchenne muscular dystrophy (DMD) – Ward L et al, October 12, 16:00-17:30 ADT, #P.71
Result of daily regimens of prednisone, deflazacort, and vamorolone on motor function in patients with Duchenne muscular dystrophy – McDonald C et al, October 14, 14:30-16:00 ADT, #P.133
Presentations and posters will be available under this link from October 11, 2022, 16:00 ADT.
“The data being presented by our academic collaborators will foster further understanding of the potential of a dissociative steroid, such as vamorolone, in maintaining muscle strength whilst addressing important safety concerns in the treatment of DMD,” said Shabir Hasham, MD, Chief Medical Officer of Santhera.
Santhera is hosting an on-site scientific exhibit (booth #4, located in the Ballroom Salon) where medical representatives of the Company will be present throughout the conference.
About Vamorolone
Vamorolone is an investigational drug candidate with a mode of action based on binding to the same receptor as corticosteroids but modifying its downstream activity and as such is considered a dissociative anti-inflammatory drug [2-5]. This mechanism has shown the potential to ‘dissociate’ efficacy from steroid safety concerns and therefore vamorolone could emerge as an alternative to existing corticosteroids, the current standard of care in children and adolescent subjects with DMD. Vamorolone has been granted Orphan Drug status in the U.S. and in Europe for DMD, and has received Fast Track and Rare Pediatric Disease designations by the U.S. FDA and Promising Innovative Medicine (PIM) status from the UK MHRA for DMD. Vamorolone is an investigational medicine and is currently not approved for use by any health authority.
[1]         Guglieri M et al (2022). JAMA Neurol. Published online August 29, 2022. doi:10.1001/jamaneurol.2022.2480. Link.
[2]        Mah JK et al (2022). JAMA Netw Open. 2022;5(1):e2144178. doi:10.1001/jamanetworkopen.2021.44178. Link.
[3]         Guglieri, et al (2022) JAMA. doi:10.1001/jama.2022.4315
[4]         Heier CR at al (2019). Life Science Alliance DOI: 10.26508
[5]         Liu X, et al (2020). Proc Natl Acad Sci USA 117:24285-24293
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The Company plans to complete the rolling submission of its filing for approval for vamorolone with the U.S. FDA in Q4-2022. The clinical stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber’s hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit
Raxone® is a trademark of Santhera Pharmaceuticals.
About ReveraGen BioPharma
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen’s lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan’s Quest, Alex’s Wish, DuchenneUK, Pietro’s Fight, Michael’s Cause, Duchenne Research Fund, and Defeat Duchenne Canada. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020).

For further information please contact:
Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, CH-4133 Pratteln
[email protected] or
Eva Kalias, Head Investor Relations & Communications
Phone: +41 79 875 27 80
[email protected]
ReveraGen BioPharma
Eric Hoffman, PhD, President and CEO
Phone: + 1 240-672-0295
[email protected]

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
2022 10 10_WMS_e_final

Related Quotes
Warwick University has been nominated for two international awards for its Esports programme.
Shares of Novavax (NASDAQ: NVAX) were jumping 6.3% as of 10:44 a.m. ET on Monday. The nice gain came after the company announced that Swiss regulators have recommended Novavax's COVID-19 vaccine Nuvaxovid as a booster in adults ages 18 and older. Novavax also announced on Monday morning that its partner, SK bioscience, has filed for approval in South Korea for Nuvaxovid to be used as a booster in adults.
A Triangle company is getting a big payout after its contract involving a Covid vaccine was canceled.
Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited
At the same time, fellow biotech company Axsome Therapeutics (NASDAQ: AXSM) is getting its moment in the spotlight. Moderna shares have dropped 50% so far this year. Sure, Moderna is generating billions of dollars from its coronavirus vaccine now.
Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
Findings may lead to better understanding of psychiatric conditions like PTSD
15 those already on Medicare can make changes to their coverage as needed. This is known as the Medicare ​a​nnual ​e​nrollment period. Read: Sticking with your Medicare plan this open enrollment season?
Many families across the U.S. lack access to supplies essential to their baby's well-being, including clothing, food, and diapers.
A new poll shows that only 49% of adults in the U.S. plan to get a flu vaccine. CBS News medical contributor Dr. Celine Gounder joins "CBS Mornings" to explain who is most at risk for getting the flu and why now is the time to get the flu vaccine.
Brian Kelly updated the status of the two offensive linemen after Saturday's loss to Tennessee.
Merck's shares rose 2.5% at $89.79 in premarket trading. Sotatercept, when compared to placebo, significantly extended how far patients with pulmonary arterial hypertension (PAH) could walk in six minutes. Merck last year bought Acceleron to gain access to the treatment sotatercept, as it sought to bulk up its pipeline ahead of blockbuster cancer drug Keytruda losing key patents in 2028.
The Inflation Reduction Act may affect how some beneficiaries want or need to structure their coverage
NY's flu tally this season so far is four times higher than last year, as fears of an especially tough fall-winter for respiratory illnesses looms
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
Jimmy Kimmel is sharing an update on his 5-year-old son Billy Kimmel's health following multiple heart surgeries.
Some experts worry that lower booster rates will help the virus mutate this fall and winter.
InnovAge made a big splash with its IPO in March 2021. A year and a half later, its enrollment was capped in two different states because of resource shortages, and its stock price had fallen by 85%. Now it's trying to make a comeback.
Getting rest days in between workouts is important for recovery
First lady Jill Biden recently discussed helping her friend recover from an abortion in Pennsylvania in the late 1960s when the procedure was illegal and warned that “extremist Republicans” will push for more restrictions on abortion now that Roe v. Wade has been overturned.


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort